Iradimed Co Net Assets
Iradimed Co net assets. Based on the latest financial reports, Iradimed Co (IRMD) has net assets worth $101.75 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($114.97 Million) and total liabilities ($13.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IRMD shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $101.75 Million |
| % of Total Assets | 88.5% |
| Annual Growth Rate | 29.7% |
| 5-Year Change | 31.1% |
| 10-Year Change | 196.71% |
| Growth Volatility | 73.51 |
Net Assets of Iradimed Co (2012–2025)
Net assets of Iradimed Co from 2012 to 2025. This chart illustrates how Iradimed Co's net assets have evolved over time, based on quarterly financial data. See IRMD net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Iradimed Co (2012–2025)
The table below shows the annual net assets of Iradimed Co from 2012 to 2025. For live market cap and overall valuation, see market value of Iradimed Co.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $94.62 Million | +8.98% |
| 2024-12-31 | $86.82 Million | +21.56% |
| 2023-12-31 | $71.42 Million | -3.06% |
| 2022-12-31 | $73.67 Million | +2.08% |
| 2021-12-31 | $72.17 Million | +17.58% |
| 2020-12-31 | $61.38 Million | +10.55% |
| 2019-12-31 | $55.52 Million | +32.37% |
| 2018-12-31 | $41.95 Million | +27.38% |
| 2017-12-31 | $32.93 Million | +3.27% |
| 2016-12-31 | $31.89 Million | -0.14% |
| 2015-12-31 | $31.93 Million | +52.86% |
| 2014-12-31 | $20.89 Million | +285.24% |
| 2013-12-31 | $5.42 Million | +68.40% |
| 2012-12-31 | $3.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Iradimed Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5544.2% over the analyzed period, indicating profitable operations and earnings retention.
Iradimed Co Net Assets Breakdown (December 2025)
Iradimed Co net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $64.23 Million | 67.88% |
| Common Stock | $1.00K | 0.00% |
| Other Components | $30.39 Million | 32.11% |
| Total Equity | $94.62 Million | 100.00% |
Iradimed Co Competitors by Market Cap
The table below lists competitors of Iradimed Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anhui Water Resources Development Co Ltd
SHG:600502
|
$1.04 Billion |
|
Drägerwerk AG & Co. KGaA (pref)
F:DRW3
|
$1.04 Billion |
|
MYT Netherlands Parent BV
NYSE:MYTE
|
$1.04 Billion |
|
Medartis Holding AG
SW:MED
|
$1.04 Billion |
|
Dongwon Ind
KO:006040
|
$1.04 Billion |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
$1.04 Billion |
|
China Railway Tielong Container Logistics Co Ltd
SHG:600125
|
$1.04 Billion |
|
Paradise Co. Ltd
KQ:034230
|
$1.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Iradimed Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 86,818,756 to 94,618,000, a change of 7,799,244 (9.0%).
- Net income of 22,480,000 contributed positively to equity growth.
- Dividend payments of 15,040,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $22.48 Million | +23.76% |
| Dividends Paid | $15.04 Million | -15.9% |
| Other Changes | $359.24K | +0.38% |
| Total Change | $- | 8.98% |
Book Value vs Market Value Analysis
This analysis compares Iradimed Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 262.36x to 11.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.31 | $81.11 | x |
| 2013-12-31 | $0.52 | $81.11 | x |
| 2014-12-31 | $2.04 | $81.11 | x |
| 2015-12-31 | $2.54 | $81.11 | x |
| 2016-12-31 | $2.66 | $81.11 | x |
| 2017-12-31 | $2.81 | $81.11 | x |
| 2018-12-31 | $3.46 | $81.11 | x |
| 2019-12-31 | $4.52 | $81.11 | x |
| 2020-12-31 | $4.93 | $81.11 | x |
| 2021-12-31 | $5.73 | $81.11 | x |
| 2022-12-31 | $5.83 | $81.11 | x |
| 2023-12-31 | $5.61 | $81.11 | x |
| 2024-12-31 | $6.79 | $81.11 | x |
| 2025-12-31 | $7.36 | $81.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Iradimed Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.76%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.82%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.15x
- Recent ROE (23.76%) is above the historical average (18.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 30.00% | 12.57% | 1.38x | 1.72x | $644.07K |
| 2013 | 35.72% | 17.08% | 1.62x | 1.29x | $1.39 Million |
| 2014 | 9.81% | 13.10% | 0.67x | 1.12x | $-38.70K |
| 2015 | 23.58% | 23.83% | 0.90x | 1.10x | $4.34 Million |
| 2016 | 22.62% | 22.20% | 0.87x | 1.17x | $4.03 Million |
| 2017 | 1.52% | 2.17% | 0.59x | 1.18x | $-2.79 Million |
| 2018 | 15.03% | 20.71% | 0.63x | 1.15x | $2.11 Million |
| 2019 | 17.35% | 25.00% | 0.58x | 1.20x | $4.08 Million |
| 2020 | 2.23% | 4.32% | 0.45x | 1.16x | $-4.77 Million |
| 2021 | 12.92% | 22.30% | 0.50x | 1.15x | $2.11 Million |
| 2022 | 17.41% | 24.06% | 0.62x | 1.16x | $5.46 Million |
| 2023 | 24.07% | 26.22% | 0.71x | 1.29x | $10.05 Million |
| 2024 | 22.15% | 26.26% | 0.74x | 1.13x | $10.55 Million |
| 2025 | 23.76% | 26.82% | 0.77x | 1.15x | $13.02 Million |
Industry Comparison
This section compares Iradimed Co's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Iradimed Co (IRMD) | $101.75 Million | 30.00% | 0.13x | $1.04 Billion |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Iradimed Co
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs moni… Read more